Biohaven Ltd.
BHVNStock
$14.17+12.07%52W
Market Cap$2.24B
P/E—
Div yield—
Beta2.98
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)17.12%
Price vs S&P 500 (4W)22.31%
VGM Score65.82
Market Capitalization$2.24B
Earnings Surprise History
Q1 26-0.88est. -0.84
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.04
4.04
4.04
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BHVNBiohaven Ltd. | — | — | B | $14.17 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Biohaven is a clinical-stage biopharmaceutical company developing treatments across immunology, neuroscience, and oncology. Its pipeline targets neuromuscular diseases, metabolic disorders, obsessive-compulsive disorder, and cancer, utilizing multiple therapeutic modalities including glutamate modulators, myostatin inhibitors, ion channel modulators, and antibody-drug conjugates. The company has multiple product candidates spanning these therapeutic areas at various development stages.